Irinotekan Kabi

Irinotecan, the active ingredient in Irinotekan Kabi, is a topoisomerase I inhibitor presented as an intravenous solution for infusion use. It is employed in the treatment of metastatic colorectal cancer, adjuvant colon cancer, and small cell lung cancer in adult patients. The product conforms to European Union pharmaceutical standards and is supplied under a prescription‑only status.

GNH USA supplies Irinotekan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. Our distribution network ensures timely delivery and regulatory compliance across multiple regions.

Irinotekan Kabi, a topoisomerase I inhibitor, is indicated for several solid‑tumor malignancies. - Metastatic colorectal cancer: improves overall survival and disease control in adult patients. - Adjuvant treatment of colon cancer: reduces risk of postoperative recurrence after curative resection. - Small cell lung cancer: contributes to tumor response when used in combination chemotherapy regimens.

Irinotekan Kabi is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: frequent gastrointestinal upset. - Vomiting: may occur during or after infusion. - Diarrhea: can be severe and require supportive care. - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: hair loss affecting scalp and body hair. - Fatigue: generalized tiredness and weakness.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent treatment. - Severe colitis or ileus: intense intestinal inflammation leading to obstruction. - Allergic reactions: including rash, pruritus, or anaphylaxis. - Hepatic toxicity: elevated liver enzymes or jaundice. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Electrolyte disturbances: severe hypokalemia or hyponatremia.

Prior to initiating Irinotekan Kabi therapy, clinicians should evaluate several safety considerations. - Baseline blood counts: monitor neutrophils, platelets, and hemoglobin regularly. - Liver function: assess transaminases and bilirubin before and during treatment. - Bowel status: avoid use in patients with recent or active gastrointestinal obstruction. - Concomitant myelosuppressants: adjust dose when combined with other bone‑marrow‑suppressing agents. - Dose adjustments: consider renal or hepatic impairment when determining infusion rates. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotekan Kabi may interact with other medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): decrease SN‑38 exposure. - UGT1A1 inhibitors (e.g., atazanavir): increase SN‑38 levels and toxicity. - Concurrent myelosuppressive chemotherapy: heighten risk of severe neutropenia. - High‑dose radiation therapy: may exacerbate bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: increase risk of ileus and constipation. - Warfarin: potential alteration of INR and bleeding risk. - Diuretics: may worsen electrolyte imbalances during diarrhea. - Antidepressants (SSRIs): monitor for serotonin syndrome when combined with other serotonergic drugs.